Retrospective Analysis of Viral Hepatitis B Incidence in Russia from 2013 to 2017 in the Context of Preventive Vaccination

The article presents the results of a retrospective analysis of viral hepatitis B incidence in the Russian Federation from 2013 to 2017, taking into account the use of vaccines included into the National Immunisation Schedule and the Immunisation Programme in Case of Epidemic Outbreaks. The analysis of the data revealed a trend towards a reduction in the incidence of acute and chronic forms of hepatitis B in the territory of the Russian Federation during the past five years. The reduction of viral hepatitis B incidence was achieved thanks to a higher vaccination coverage of both children and adults. The article presents an overview of monovalent and combination recombinant hepatitis B vaccines licensed in the Russian Federation. It describes the WHO position on preventive vaccination against viral hepatitis B, and pays special attention to vaccination of people at risk. The article considers promising areas for improving immunobiological products for hepatitis B prevention, including new technologies used in vaccine production, development and introduction of new adjuvants or adjuvants systems, and development of therapeutic vaccines.

1. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viral interactions and management. Ann Gastroenterol. 2015;28(2):221–8.

2. Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014;20(18):5427–34. https://doi.org/10.3748/wjg.v20.i18.5427

3. Kramvis A. The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics. Rev Med Virol. 2016;26(4):285–303. https://doi.org/10.1002/rmv.1885

4. Озерецковский НА, Шалунова НВ, Петручук ЕМ, Индикова ИН. Вакцинопрофилактика гепатита B. Эпидемиология и вакцинопрофилактика. 2015;2(81):87–95. [Ozeretskovsky NA, Shalunova NV, Petruchuk EM, Indikova IN. Vaccinoprophylaxis of hepatitis B. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccine Prevention. 2015;2(81):87–95 (In Russ.)]

5. Heijtink RA, Bergen PV, Melber K, Janowicz ZA, Osterhaus AD. Hepatitis B surface antigen (HBsAg) derived from yeast cells (Hansenula polymorpha) used to establish an influence of antigenic subtype (adw2, adr, ayw3) in measuring the immune response after vaccination. Vaccine. 2002;20(17–18):2191–6. https://doi.org/10.1016/S0264-410X(02)00145-7

6. Shimakawa Y, Lemoine M, Bottomley C, Njai HF, Ndow G, Jatta A, et al. Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case-control study in the Gambia. Liver Int. 2015;35(10):2318–26. https://doi.org/10.1111/liv.12814

7. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15(2):223–43. https://doi.org/10.1016/j.cld.2011.03.006

8. Peters RL. Viral hepatitis: a pathologic spectrum. Am J Med Sci. 1975;270(1):17–31.

9. Van Damme P, Ward J, Shouval D, Wiersma S, Zanetti A. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 7th ed. Elsevier Saunders; 2017. P. 342–75.

10. Klushkina VV, Kyuregyan KK, Kozhanova TV, Popova OE, Dubrovina PG, Isaeva OV, et al. Impact of universal hepatitis B vaccination on prevalence, infection-associated morbidity and mortality, and circulation of immune escape variants in Russia. PLoS One. 2016;11(6):e0157161. https://doi.org/10.1371/journal.pone.0157161

11. Шахгильдян ИВ, Михайлов МИ, Онищенко ГГ. Парентеральные вирусные гепатиты (эпидемиология, диагностика, профилактика). М.: ГОУ ВУНМЦ МЗ РФ; 2003. [Shakhgildyan IV, Mikhailov MI, Onishchenko GG. Parenteralnye virusnye gepatity (epidemiologiya, diagnostika, profilaktika). Moscow: GOU VUNMTS MZ RF; 2003 (In Russ.)]

12. Шульгина НИ, Стасенко ВЛ. Оценка эффективности массовой иммунизации населения против гепатита В в Новосибирской области. Сибирский медицинский журнал (Иркутск). 2011;100(1):125–8. [Shulginа NI, Stasenko VL. Estimation of efficiency of mass immunization of the population against hepatitis B in Novosibirsk oblast. Sibirskij medicinskij zhurnal (Irkutsk) = Siberian Medical Journal (Irkutsk). 2011;100(1):125–8 (In Russ.)]

13. Lin AW, Wong KH. Long-term protection of neonatal hepatitis B vaccination in a 30-year cohort in Hong Kong. J Hepatol. 2013;59(6):1363–4. https://doi.org/10.1016/j.jhep.2013.08.021

14. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9):1390–6. https://doi.org/10.1086/606119

15. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database of Syst Rev. 2006;(2):CD004790. https://doi.org/10.1002/14651858.CD004790.pub2

16. Van Den Ende C, Marano C, Van Ahee A, Bunge EM, De Moerlooze L. The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience. Expert Rev Vaccines. 2017;16(8):811–32. https://doi.org/10.1080/14760584.2017.1338568

17. Акимкин ВГ, Семененко ТА. Эпидемиологическая и иммунологическая эффективность вакцинации медицинских работников против гепатита В. Эпидемиология и вакцинопрофилактика. 2017;16(4):52–7. [Akimkin VG, Semenenko TA. Epidemiological and immunological efficacy of health workers vaccination against hepatitis B. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccine Prevention. 2017;16(4):52–7 (In Russ.)] https://doi.org/10.31631/2073-3046-2017-16-4-52-57

18. Фельдблюм ИВ, Николаева АМ, Павроз КА, Данилина ТВ, Соснина ОЮ, Вязникова ТВ и др. Безопасность и иммуногенность отечественной комбинированной вакцины против коклюша, дифтерии, столбняка, гепатита В и Hib-инфекции, содержащей бесклеточный коклюшный компонент, при иммунизации взрослых. Журнал микробиологии, эпидемиологии и иммунобиологии. 2016;(1):46–51. [Feldblyum IV, Nikolaeva AM, Pavroz KA, Danilina TV, Sosnina OYu, Vyaznikova TV, et al. Safety and immunogenicity of a national combined vaccine against pertussis, diphtheria, tetanus, hepatitis B and Hib-infection, containing acellular pertussis component, during immunization of adults. Zhurnal mikrobiologii, ehpidemiologii i immunobiologii = Journal of Microbiology, Epidemiology and Immunology. 2016;(1):46–51 (In Russ.)]

19. Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine. 2010;28(3):623–31. https://doi.org/10.1016/j.vaccine.2009.10.068

20. Mikaeloff Y, Caridade G, Assi S, Tardieu M, Suissa S. Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. Brain. 2007;130(4):1105–10. https://doi.org/10.1093/brain/awl368

21. Yu O, Bohlke K, Hanson CA, Delaney K, Rees TG, Zavitkovsky A, et al. Hepatitis B vaccine and risk of autoimmune thyroid disease: a vaccine safety datalink study. Pharmacoepidemiol Drug Saf. 2007;16(7):736–45. https://doi.org/10.1002/pds.1354

22. Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin Drug Saf. 2003;2(3):225–31. https://doi.org/10.1517/14740338.2.3.225

23. Gerlich WH. Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol. 2015;204(1):39–55. https://doi.org/10.1007/s00430-014-0373-y

24. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther. 2008;8(2):235–47. https://doi.org/10.1517/14712598.8.2.235

25. Leroux-Roels G. Old and new adjuvants for hepatitis B vaccines. Med Microbiol Immunol. 2015;204(1):69–78. https://doi.org/10.1007/s00430-014-0375-9

26. Gish RG, Given BD, Lai CL, Locarnini SA, Lau JY, Lewis DL, Schluep T. Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities. Antiviral Res. 2015;(121):47–58. https://doi.org/10.1016/j.antiviral.2015.06.008

27. Лобаина Мато Я, Агилар Рубидо Х, Гильен Нието Х. ABX203, инновационная терапевтическая вакцина для больных хроническим гепатитом В. Альманах клинической медицины. 2016;44(6):713–18. [Lobaina Mato Y, Aguilar Rubido J, Guillén Nieto G. ABX203, a novel therapeutic vaccine for chronic hepatitis B patients. Almanah klinicheskoj mediciny = Almanac of Clinical Medicine. 2016;44(6):713–18 (In Russ.)] https://doi.org/10.18786/2072-0505-2016-44-6-713-718

28. Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol. 2011;54(6):1286–96. https://doi.org/10.1016/j.jhep.2010.12.031

29. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010;138(2):682–93. https://doi.org/10.1053/j.gastro.2009.09.052